Background: Acute myocardial infarction (AMI) triggers local inflammation in the injured myocardium, followed by a systemic inflammatory response of lymphatic organs. This prospective trial investigated whether molecular imaging of lymphatic organs (spleen, bone marrow, and heart-draining lymph nodes (LN)) identifies individuals predisposed to functional recovery during follow-up after AMI. Methods: 41 timely re-perfused ST-elevation AMI patients received positron emission tomography (PET) using 68Ga-PentixaFor, a radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4) post-AMI. Patients were allocated to an early (2-4 days) or late PET imaging group (5-8 d) based on tracer availability. To determine left ventricular ejection fraction (LVEF) and infarct size, cardiac magnetic resonance imaging was conducted at baseline and repeated after six (follow-up (FU) 1, available in 38/41) and twelve months (FU 2, 36/41). As endpoint, an LVEF increase of ≥5% relative to baseline was then defined as short- (at FU 1) and long-term functional (at FU 2) recovery. We also determined association of 68Ga-PentixaFor uptake in the infarct territory and lymphatic organs with outcome relative to established clinical and imaging biomarkers. Results: At FU 1, functional recovery was recorded in 21/38 patients. Univariate analysis identified baseline LVEF (Odds Ratio (OR), 0.80, P=0.002) and uptake derived from heart-draining LN (OR, 0.21, P=0.03) as predictor of functional recovery, while only LVEF reached significance at multivariate analysis (OR, 0.72, P=0.007). At FU 2, functional recovery was observed in 21/36 patients and LVEF (OR, 0.84, P=0.005) and splenic PET signal (OR, 2.46, P=0.04) provided prognostic value at univariate analysis. Both parameters remained significant at multivariate outcome analysis (LVEF: OR, 0.73, P=0.01; spleen: OR, 4.17, P=0.04), indicating that low baseline LVEF and high splenic tracer uptake are prognostic for improved long-term functional outcome. Established risk factors of cardiac damage (infarct size) or inflammation (C-reactive protein, white blood cell counts) failed to reach significance for functional recovery at FU 1 and FU 2. Conclusions: Along with baseline EF, imaging of chemokine receptor expression in the spleen provides a complementary in-vivo biomarker for long-term functional recovery. Whole-body PET-based assessment of systemic inflammatory response in lymphatic organs may therefore open avenues for immune modulation strategies in patients after AMI.
Reiter et al. (2025) studied this question.